Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...

Canaccord Genuity analyst Edward Nash has maintained their bullish stance on CORT stock, giving a Buy rating on December 6.Pick the best ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Lee covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Argenx Se, and Wave Life Sciences. Currently, the analyst consensus on Corcept Therapeutics is a Strong Buy with an ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) have been assigned an average rating of “Buy” ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics Incorporated (CORT) stock saw a decline, ending the day at $59.26 which represents a decrease of $-1.52 or -2.50% from the prior close of $60.78. The stock opened at $60.81 and ...